Effect of APOE ε4 allele on cortical thicknesses and volumes: The addNeuroMed study

Journal of Alzheimer's Disease

Volumn 21, Issue 3, 2010, Pages 947-966

  Liu, Yawu ^a   Paajanen, Teemu ^a   Westman, Eric ^b   Wahlund, Lars Olof ^b   Simmons, Andrew ^c   Tunnard, Catherine ^c   Sobow, Tomasz ^d   Proitsi, Petroula ^c   Powell, John ^c   Mecocci, Patrizia ^e   Tsolaki, Magda ^f   Vellas, Bruno ^g   Muehlboeck, Sebastian ^h   Evans, Alan ^h   Spenger, Christian ^b   Lovestone, Simon ^c   Soininen, Hilkka ^a  

^a KUOPIO UNIVERSITY HOSPITAL   (Finland)

^b KAROLINSKA INSTITUTE   (Sweden)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d MEDICAL UNIVERSITY OF LODZ   (Poland)

^e UNIVERSITY OF PERUGIA   (Italy)

^f ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^g TOULOUSE UNIVERSITY HOSPITAL   (France)

^h MCGILL UNIVERSITY   (Canada)

Author keywords

Alzheimer's disease; apolipoprotein E; MR imaging; thickness; volume

Indexed keywords

APOLIPOPROTEIN E4;

AGED; ALLELE; ALZHEIMER DISEASE; AMYGDALOID NUCLEUS; ARTICLE; BRAIN CORTEX; BRAIN SIZE; CAUDATE NUCLEUS; CINGULATE GYRUS; CONTROLLED STUDY; FEMALE; HIPPOCAMPUS; HOMOZYGOSITY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; ORBITAL CORTEX; PRIORITY JOURNAL; THICKNESS;

EID: 77957253668     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2010-100201     Document Type: Article

References (51)

1. Mahley RW, Rall SC, Jr. (2000) Apolipoprotein E: far more than a lipid transport protein. Annu Rev Genomics Hum Genet 1, 507537.
2. Jiang Q, Lee CY,Mandrekar S,Wilkinson B, Cramer P, Zelcer N,Mann K, Lamb B,Willson TM, Collins JL, Richardson JC, Smith JD, Comery TA, Riddell D, Holtzman DM, Tontonoz P, Landreth GE (2008) APOE promotes the proteolytic degradation of Abeta. Neuron 58, 681693. (Pubitemid 351778466)
3. Cherbuin N, Leach LS, Christensen H, Anstey KJ (2007) Neuroimaging and APOE genotype: A systematic qualitative review. Dement Geriatr Cogn Disord 24, 348362. (Pubitemid 350036691)
4. Bookheimer S, Burggren A (2009) APOE4 genotype and neurophysiological vulnerability to Alzheimer's and cognitive aging. Annu Rev Clin Psychol 5, 343362.
5. Barboriak DP, Doraiswamy PM, Krishnan KR, Vidyarthi S, Sylvester J, Charles HC (2000) Hippocampal sulcal cavities on MRI: Relationship to age and apolipoprotein E genotype. Neurology 54, 21502153. (Pubitemid 30397218)
6. Den Heijer T, Oudkerk M, Launer LJ, Van Duijn CM, Hofman A, Breteler MM (2002) Hippocampal, amygdalar, and global brain atrophy in different apolipoprotein E genotypes. Neurology 59, 746748.
7. Farlow MR, He Y, Tekin S, Xu J, Lane R, Charles HC (2004) Impact of APOE in mild cognitive impairment. Neurology 63, 18981901. (Pubitemid 39532387)
8. Fleisher A, GrundmanM, Jack CR, Jr., Petersen RC, Taylor C, Kim HT, Schiller DH, Bagwell V, Sencakova D, Weiner MF, DeCarli C, DeKosky ST, Van Dyck CH, Thal LJ (2005) Sex, apolipoprotein E epsilon 4 status, and hippocampal volume in mild cognitive impairment. Arch Neurol 62, 953957. (Pubitemid 40973457)
9. Lind J, Larsson A, Persson J, Ingvar M, Nilsson LG, Backman L, Adolfsson R, Cruts M, Sleegers K, Van Broeckhoven C, Nyberg L (2006) Reduced hippocampal volume in nondemented carriers of the apolipoprotein E epsilon4: Relation to chronological age and recognition memory. Neurosci Lett 396, 2327. (Pubitemid 43233781)
10. SerraGrabulosa JM, SalgadoPineda P, Junque C, SolePadulles C, Moral P, LopezAlomar A, Lopez T, LopezGuillen A, Bargallo N, Mercader JM, Clemente IC, BartresFazD (2003) Apolipoproteins E and C1 and brainmorphology in memory impaired elders. Neurogenetics 4, 141146. (Pubitemid 36612197)
11. Soininen H, Partanen K, Pitkanen A, Hallikainen M, Hanninen T, Helisalmi S, Mannermaa A, Ryynanen M, Koivisto K, Riekkinen P, Sr. (1995) Decreased hippocampal volume asymmetry on MRIs in nondemented elderly subjects carrying the apolipoprotein E epsilon 4 allele. Neurology 45, 391392.
12. Tohgi H, Takahashi S, Kato E, Homma A, Niina R, Sasaki K, Yonezawa H, Sasaki M (1997) Reduced size of right hip pocampus in 39to 80yearold normal subjects carrying the apolipoprotein E epsilon4 allele. Neurosci Lett 236, 2124. (Pubitemid 27492069)
13. BassoM, Gelernter J, Yang J,MacAvoy MG, Varma P, Bronen RA, Van Dyck CH (2006) Apolipoprotein E epsilon4 is associated with atrophy of the amygdala in Alzheimer's disease. Neurobiol Aging 27, 14161424. (Pubitemid 44279892)
14. Hashimoto M, Yasuda M, Tanimukai S, Matsui M, Hirono N, Kazui H, Mori E (2001) Apolipoprotein E epsilon 4 and the pattern of regional brain atrophy in Alzheimer's disease. Neurology 57, 14611466. (Pubitemid 32995729)
15. Lehtovirta M, Laakso MP, Soininen H, Helisalmi S, Mannermaa A, Helkala EL, Partanen K, Ryynanen M, Vainio P, Hartikainen P, Riekkinen Sr PJ (1995) Volumes of hippocampus, amygdala and frontal lobe in Alzheimer patients with different apolipoprotein E genotypes. Neuroscience 67, 6572.
16. Lehtovirta M, Soininen H, Laakso MP, Partanen K, Helisalmi S, Mannermaa A, Ryynanen M, Kuikka J, Hartikainen P, Riekkinen PJ, Sr. (1996) SPECT and MRI analysis in Alzheimer's disease: Relation to apolipoprotein E epsilon 4 allele. J Neurol Neurosurg Psychiatry 60, 644649. (Pubitemid 126728355)
17. Geroldi C, PihlajamakiM, LaaksoMP,DeCarli C, Beltramello A, Bianchetti A, Soininen H, Trabucchi M, Frisoni GB (1999) APOEepsilon4 is associatedwith less frontal andmoremedial temporal lobe atrophy in AD. Neurology 53, 18251832. (Pubitemid 29530361)
18. Juottonen K, Lehtovirta M, Helisalmi S, Riekkinen PJ, Sr., Soininen H (1998) Major decrease in the volume of the entorhinal cortex in patients with Alzheimer's disease carrying the apolipoprotein E epsilon4 allele. J Neurol Neurosurg Psychiatry 65, 322327. (Pubitemid 28408245)
19. Shaw P, Lerch JP, Pruessner JC, Taylor KN, Rose AB, Greenstein D, Clasen L, Evans A, Rapoport JL, Giedd JN (2007) Cortical morphology in children and adolescents with different apolipoprotein E gene polymorphisms: An observational study. Lancet Neurol 6, 494500. (Pubitemid 46734757)
20. DeCarli C, Reed T, Miller BL, Wolf PA, Swan GE, Carmelli D (1999) Impact of apolipoprotein E epsilon4 and vascular disease on brain morphology in men from the NHLBI twin study. Stroke 30, 15481553. (Pubitemid 29379601)
21. Wahlund LO, Julin P, Lannfelt L, Lindqvist J, Svensson L (1999) Inheritance of the APOE epsilon4 allele increases the rate of brain atrophy in dementia patients. Dement Geriatr Cogn Disord 10, 262268. (Pubitemid 29281016)
22. Carmelli D, DeCarli C, Swan GE, KellyHayes M, Wolf PA, Reed T, Guralnik JM(2000) The joint effect of apolipoprotein E epsilon4 and MRI findings on lowerextremity function and decline in cognitive function. J Gerontol A Biol Sci Med Sci 55, M103109. (Pubitemid 30165504)
23. Espeseth T, Greenwood PM, Reinvang I, Fjell AM, Walhovd KB,Westlye LT,Wehling E, Lundervold A, Rootwelt H, Parasuraman R (2006) Interactive effects of APOE and CHRNA4 on attention and white matter volume in healthy middleaged and older adults. Cogn Affect Behav Neurosci 6, 3143. (Pubitemid 44237731)
24. Reiman EM,Uecker A, Caselli RJ, Lewis S, Bandy D, De Leon MJ, De Santi S, Convit A, Osborne D, Weaver A, Thibodeau SN (1998) Hippocampal volumes in cognitively normal persons at genetic risk for Alzheimer's disease. Ann Neurol 44, 288291. (Pubitemid 28374124)
25. Schmidt H, Schmidt R, Fazekas F, Semmler J, Kapeller P, Reinhart B, Kostner GM (1996) Apolipoprotein E e4 allele in the normal elderly: neuropsychologic and brain MRI correlates. Clin Genet 50, 293299. (Pubitemid 27019657)
26. Jack CR, Jr., Petersen RC, Xu Y, O'Brien PC, Smith GE, Ivnik RJ, Tangalos EG, Kokmen E (1998) Rate of medial temporal lobe atrophy in typical aging and Alzheimer's disease. Neurology 51, 993999. (Pubitemid 28473390)
27. Jack CR, Jr., Petersen RC, Xu YC, O'Brien PC, Waring SC, Tangalos EG, Smith GE, Ivnik RJ, Thibodeau SN, Kokmen E (1998) Hippocampal atrophy and apolipoprotein E genotype are independently associated with Alzheimer's disease. Ann Neurol 43, 303310. (Pubitemid 28113592)
28. Barber R, Ballard C, McKeith IG, Gholkar A, O'Brien JT (2000) MRI volumetric study of dementia with Lewy bodies: A comparison with AD and vascular dementia. Neurology 54, 13041309. (Pubitemid 30174051)
29. Drzezga A, Grimmer T, Henriksen G, Muhlau M, Perneczky R, Miederer I, Praus C, Sorg C, Wohlschlager A, Riemenschneider M, Wester HJ, Foerstl H, Schwaiger M, Kurz A (2009) Effect of APOE genotype on amyloid plaque load and graymatter volume inAlzheimer disease. Neurology 72, 14871494.
30. Du AT, Schuff N, Chao LL, Kornak J, Jagust WJ, Kramer JH, Reed BR, Miller BL, Norman D, Chui HC, Weiner MW (2006) Age effects on atrophy rates of entorhinal cortex and hippocampus. Neurobiol Aging 27, 733740.
31. Enzinger C, Fazekas F, Matthews PM, Ropele S, Schmidt H, Smith S, Schmidt R (2005) Risk factors for progression of brain atrophy in aging: sixyear followup of normal subjects. Neurology 64, 17041711. (Pubitemid 40695802)
32. Tanaka S, Kawamata J, Shimohama S, Akaki H, Akiguchi I, Kimura J, Ueda K (1998) Inferior temporal lobe atrophy and APOE genotypes in Alzheimer's disease. Xray computed tomography, magnetic resonance imaging and Xe133 SPECT studies. Dement Geriatr Cogn Disord 9, 9098.
33. Lemaitre H, Crivello F, Dufouil C, Grassiot B, Tzourio C, Alperovitch A, Mazoyer B (2005) No epsilon4 gene dose effect on hippocampal atrophy in a large MRI database of healthy elderly subjects. Neuroimage 24, 12051213. (Pubitemid 40164522)
34. WishartHA, SaykinAJ,McAllister TW, Rabin LA,McDonald BC, Flashman LA, Roth RM, Mamourian AC, Tsongalis GJ, Rhodes CH(2006)Regional brain atrophy in cognitively intact adultswith a singleAPOE epsilon4 allele.Neurology 67, 12211224.
35. Pievani M, Rasser PE, Galluzzi S, Benussi L, Ghidoni R, Sabattoli F, Bonetti M, Binetti G, Thompson PM, Frisoni GB (2009) Mapping the effect of APOE epsilon4 on gray matter loss in Alzheimer's disease in vivo. Neuroimage 45, 10901098.
36. Pennanen C, Testa C, BoccardiM, LaaksoMP, Hallikainen M, Helkala EL, Hanninen T, Kivipelto M, Kononen M, Nissinen A, Tervo S, Vanhanen M, Vanninen R, Frisoni GB, Soininen H (2006) The effect of apolipoprotein polymorphism on brain in mild cognitive impairment: A voxelbased morphometric study. Dement Geriatr Cogn Disord 22, 6066. (Pubitemid 43909830)
37. Boccardi M, Sabattoli F, Testa C, Beltramello A, Soininen H, Frisoni GB (2004) APOE and modulation of Alzheimer's and frontotemporal dementia. Neurosci Lett 356, 167170. (Pubitemid 38186678)
38. Fischl B, Dale AM (2000) Measuring the thickness of the human cerebral cortex from magnetic resonance images. Proc Natl Acad Sci U S A 97, 1105011055.
39. FischlB, SalatDH,BusaE,AlbertM,DieterichM,Haselgrove C, Van Der Kouwe A, Killiany R, Kennedy D, Klaveness S, Montillo A, Makris N, Rosen B, Dale AM (2002) Whole brain segmentation: Automated labeling of neuroanatomical structures in the human brain. Neuron 33, 341355. (Pubitemid 34162530)
40. Fischl B, Salat DH, Van Der Kouwe AJ, Makris N, Segonne F, Quinn BT, Dale AM(2004) Sequenceindependent Segmenta tion of magnetic resonance images. Neuroimage 23 Suppl 1, S6984. (Pubitemid 39429376)
41. Liu Y, Paajanen T, Zhang Y, Westman E, Wahlund LO, Simmons A, Tunnard C, Sobow T, Mecocci P, Tsolaki M, Vellas B,Muehlboeck S, Evans A, Spenger C, Lovestone S, Soininen H (2009) Combination analysis of neuropsychological tests and structural MRI measures in differentiating AD, MCI and control groupsThe AddNeuroMed study. Neurobiol Aging, in press.
42. Lovestone S, Francis P, Strandgaard K (2007) Biomarkers for diseasemodification trials - the innovativemedicines initiative and AddNeuroMed. J Nutr Health Aging 11, 359361. (Pubitemid 47121941)
43. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM(1984) Clinical diagnosis of Alzheimer's disease: Report of the NINCDSADRDA Work Group under the auspices ofDepartment ofHealth andHuman Services Task Force on Alzheimer's Disease. Neurology 34, 939944. (Pubitemid 14076461)
44. Petersen RC, Doody R, Kurz A, Mohs RC, Morris JC, Rabins PV, Ritchie K, Rossor M, Thal L, Winblad B (2001) Current concepts in mild cognitive impairment. Arch Neurol 58, 19851992. (Pubitemid 33143977)
45. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E (1999) Mild cognitive impairment: Clinical characterization and outcome. Arch Neurol 56, 303308. (Pubitemid 29120227)
46. Folstein MF, Folstein SE, McHugh PR (1975) 'Minimental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12, 189198.
47. Hughes CP, Berg L, Danziger WL, Coben LA, Martin RL (1982) A new clinical scale for the staging of dementia. Br J Psychiatry 140, 566572. (Pubitemid 12124384)
48. Rosen WG, Mohs RC, Davis KL (1984) A new rating scale for Alzheimer's disease. Am J Psychiatry 141, 13561364.
49. Hixson JE, Vernier DT (1990) Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res 31, 545548.
50. Jack CR, Jr., Bernstein MA, Fox NC, Thompson P, Alexander G, Harvey D, Borowski B, Britson PJ, J LW, Ward C, Dale AM, Felmlee JP, Gunter JL, Hill DL, Killiany R, Schuff N, FoxBosetti S, Lin C, Studholme C, DeCarli CS, Krueger G, Ward HA, Metzger GJ, Scott KT,Mallozzi R, Blezek D, Levy J, Debbins JP, Fleisher AS, Albert M, Green R, Bartzokis G, Glover G, Mugler J, Weiner MW (2008) The Alzheimer's Disease Neuroimaging Initiative (ADNI): MRI methods. J Magn Reson Imaging 27, 685691. (Pubitemid 351508080)
51. Simmons A, Westman E, Muehlboeck S, Mecocci P, Vellas B, Tsolaki M, Kloszewska I, Wahlund LO, Soininen H, Lovestone S, Evans A, Spenger C (2010) The AddNeuroMed framework for multicentre MRI assessment of longitudinal changes in Alzheimer's disease : experience from the first 24 months. Int J Ger Psych, in press.